For patients with advanced PC who are not eligible for HIPEC with curative intent, a novel treatment has recently been introduced, called ʻpressurized intraperitoneal aerosolchemotherapy (PIPAC). This technique is minimally invasive and combines the advantages of local administration withpressurized vaporization. Although no clear indication for PIPAC has yet been defined, the treatment has been reported to be feasible, well tolerated and safe. However, availabledata are limited by small sample sizes, heterogeneity and thelack of control groups.